Skip to main content

BioMarin Pharmaceutical (BMRN) Receives a Buy from Canaccord Genuity

Tipranks - Tipranks - Sat Feb 14, 6:42AM CST

Canaccord Genuity analyst Whitney Ijem maintained a Buy rating on BioMarin Pharmaceutical yesterday and set a price target of $98.00.

Valentine's Day Sale - 70% Off

According to TipRanks, Ijem is a 5-star analyst with an average return of 21.2% and a 51.54% success rate. Ijem covers the Healthcare sector, focusing on stocks such as Palvella Therapeutics, Fractyl Health, Inc., and BioMarin Pharmaceutical.

BioMarin Pharmaceutical has an analyst consensus of Moderate Buy, with a price target consensus of $88.29.

See today’s best-performing stocks on TipRanks >>

Based on BioMarin Pharmaceutical’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $776.13 million and a GAAP net loss of $30.74 million. In comparison, last year the company earned a revenue of $745.74 million and had a net profit of $106.08 million

Read More on BMRN:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).